Positive study results likely made many investors in biotech stock feel a little better Monday. Here’s some small stocks making big moves on Monday, March 13, 2017 (as of 4 pm EST):
Biotech stock DiaMedica Therapeutics Inc. (TSXV: DMA) jumped 26% to $0.27 after announcing what it called “positive results” from its Phase Ib bridging trial, designed to compare the profile of DM199 to the approved urinary KLK1 product on the market in Asia for acute ischemic stroke.
As well, shares of Aralez Pharmaceuticals Inc. (TSX: ARZ) slid 29% to $3.33 as the specialty pharmaceutical company said its GAAP net loss for fiscal 2016 widened to $103.0 million from $37.8 million during fiscal 2015.
Gran Colombia Gold Corp. (TSX: GCM), meanwhile, reported results of a small underground infill drilling program to explore the extension of the mineralization in the Marmato Underground mine, which included 8.98 metres of 20.99 g/t gold. Gran Colombia Gold stock moved up 6% to $0.095 following the announcement.
Finally, Adamera Minerals Corp. (TSXV: ADZ) gained 16% to $0.11 after the gold explorer announced that it has defined a second set of VTEM electromagnetic anomalies in the Cooke Mountain Project in Washington State. Adamera has now defined six targets that warrant testing during its upcoming drill program.
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
Biotech stock DiaMedica Therapeutics Inc. (TSXV: DMA) jumped 26% to $0.27 after announcing what it called “positive results” from its Phase Ib bridging trial, designed to compare the profile of DM199 to the approved urinary KLK1 product on the market in Asia for acute ischemic stroke.
